News & Updates

Undergoing percutaneous coronary intervention (PCI) results in improvements in angina symptoms beyond placebo in patients with symptomatic single-vessel coronary chronic total occlusion (CTO), according to a study.

The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with obstructive sleep apnoea (OSA) may reduce the incidence of cerebrovascular events, minimize healthcare use, and lower all-cause mortality, according to a retrospective study.

Administering a single dose of dextrose gel as prophylaxis against transitional neonatal hypoglycaemia does not help with the risk of neurocognitive impairment at early school age and even appears to have adverse effects on psychological well-being, according to a study.

In adolescents living with HIV, a 5-days-on and 2-days-off dosing of antiretroviral therapy (ART) with tenofovir disoproxil fumarate, lamivudine, and dolutegravir fails to match the efficacy of continuous dosing for maintaining viral suppression, as shown in the BREATHER Plus trial conducted in Africa.

Percutaneous coronary intervention (PCI) achieves greater symptom improvement in focal vs diffuse coronary artery disease (CAD), as shown in the ORBITA-2 study.

Percutaneous coronary intervention (PCI) performs better than optical medical therapy (OMT) in improving quality of life (QoL), angina frequency, and the Seattle Angina Questionnaire (SAQ) summary score in patients with a single chronic total coronary occlusion (CTO), reports a study.

In the treatment of patients with eosinophilic gastritis, the use of dupilumab helps improve histological outcomes, according to the proof-of-concept, phase II DEGAS study.